vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Strategy Inc (MSTR). Click either name above to swap in a different company.

Strategy Inc is the larger business by last-quarter revenue ($123.0M vs $62.1M, roughly 2.0× Cytek Biosciences, Inc.). On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 1.9%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 3.3%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Strategy Inc., formerly known as MicroStrategy, is an American company that provides business intelligence (BI) and mobile software. Founded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps. It is a public company headquartered in Tysons Corner, Virginia, in the Washington metropolitan area. Its primary business analytics competitors include SAP SE Busin...

CTKB vs MSTR — Head-to-Head

Bigger by revenue
MSTR
MSTR
2.0× larger
MSTR
$123.0M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+6.2% gap
CTKB
8.1%
1.9%
MSTR
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
3.3%
MSTR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CTKB
CTKB
MSTR
MSTR
Revenue
$62.1M
$123.0M
Net Profit
$-44.1M
Gross Margin
52.9%
66.1%
Operating Margin
-9.0%
Net Margin
-70.9%
Revenue YoY
8.1%
1.9%
Net Profit YoY
-557.1%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
MSTR
MSTR
Q4 25
$62.1M
$123.0M
Q3 25
$52.3M
$128.7M
Q2 25
$45.6M
$114.5M
Q1 25
$41.5M
$111.1M
Q4 24
$57.5M
$120.7M
Q3 24
$51.5M
$116.1M
Q2 24
$46.6M
$111.4M
Q1 24
$44.9M
$115.2M
Net Profit
CTKB
CTKB
MSTR
MSTR
Q4 25
$-44.1M
Q3 25
$-5.5M
$2.8B
Q2 25
$-5.6M
$10.0B
Q1 25
$-11.4M
$-4.2B
Q4 24
$9.6M
$-670.8M
Q3 24
$941.0K
$-340.2M
Q2 24
$-10.4M
$-102.6M
Q1 24
$-6.2M
$-53.1M
Gross Margin
CTKB
CTKB
MSTR
MSTR
Q4 25
52.9%
66.1%
Q3 25
52.7%
70.5%
Q2 25
52.3%
68.8%
Q1 25
48.6%
69.4%
Q4 24
58.5%
71.7%
Q3 24
56.3%
70.4%
Q2 24
54.6%
72.2%
Q1 24
51.3%
74.0%
Operating Margin
CTKB
CTKB
MSTR
MSTR
Q4 25
-9.0%
Q3 25
-17.6%
Q2 25
-23.3%
Q1 25
-36.1%
-5331.4%
Q4 24
5.2%
-842.1%
Q3 24
-8.2%
-372.7%
Q2 24
-18.3%
-179.7%
Q1 24
-23.9%
-176.8%
Net Margin
CTKB
CTKB
MSTR
MSTR
Q4 25
-70.9%
Q3 25
-10.5%
2164.1%
Q2 25
-12.2%
8752.7%
Q1 25
-27.5%
-3797.2%
Q4 24
16.8%
-555.8%
Q3 24
1.8%
-293.1%
Q2 24
-22.4%
-92.0%
Q1 24
-13.8%
-46.1%
EPS (diluted)
CTKB
CTKB
MSTR
MSTR
Q4 25
Q3 25
$8.42
Q2 25
$32.60
Q1 25
$-16.49
Q4 24
$4.49
Q3 24
$-1.72
Q2 24
$-0.57
Q1 24
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
MSTR
MSTR
Cash + ST InvestmentsLiquidity on hand
$90.9M
$2.3B
Total DebtLower is stronger
$8.2B
Stockholders' EquityBook value
$341.7M
$44.1B
Total Assets
$461.5M
$61.6B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
MSTR
MSTR
Q4 25
$90.9M
$2.3B
Q3 25
$93.3M
$54.3M
Q2 25
$75.5M
$50.1M
Q1 25
$95.3M
$60.3M
Q4 24
$98.7M
$38.1M
Q3 24
$162.3M
$46.3M
Q2 24
$177.9M
$66.9M
Q1 24
$168.8M
$81.3M
Total Debt
CTKB
CTKB
MSTR
MSTR
Q4 25
$8.2B
Q3 25
$8.2B
Q2 25
$8.2B
Q1 25
$8.1B
Q4 24
$7.2B
Q3 24
$4.2B
Q2 24
$3.8B
Q1 24
$3.6B
Stockholders' Equity
CTKB
CTKB
MSTR
MSTR
Q4 25
$341.7M
$44.1B
Q3 25
$378.6M
$52.3B
Q2 25
$377.6M
$47.5B
Q1 25
$379.6M
$32.2B
Q4 24
$395.7M
$18.2B
Q3 24
$385.5M
$3.8B
Q2 24
$389.1M
$2.8B
Q1 24
$392.6M
$2.4B
Total Assets
CTKB
CTKB
MSTR
MSTR
Q4 25
$461.5M
$61.6B
Q3 25
$494.9M
$73.6B
Q2 25
$493.3M
$64.8B
Q1 25
$482.6M
$43.9B
Q4 24
$499.5M
$25.8B
Q3 24
$491.2M
$8.3B
Q2 24
$483.7M
$7.1B
Q1 24
$492.1M
$6.4B
Debt / Equity
CTKB
CTKB
MSTR
MSTR
Q4 25
0.19×
Q3 25
0.16×
Q2 25
0.17×
Q1 25
0.25×
Q4 24
0.39×
Q3 24
1.12×
Q2 24
1.36×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
MSTR
MSTR
Operating Cash FlowLast quarter
$-771.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
MSTR
MSTR
Q4 25
$-771.0K
Q3 25
$-3.9M
$-8.3M
Q2 25
$108.0K
$-34.9M
Q1 25
$-125.0K
$-2.4M
Q4 24
$2.0M
$-17.3M
Q3 24
$13.2M
$-41.0M
Q2 24
$6.2M
$-23.3M
Q1 24
$4.0M
$28.6M
Free Cash Flow
CTKB
CTKB
MSTR
MSTR
Q4 25
$-1.8M
Q3 25
$-4.6M
$-11.1M
Q2 25
$-1.5M
$-37.0M
Q1 25
$-974.0K
$-5.1M
Q4 24
$1.1M
$-17.6M
Q3 24
$12.2M
$-41.4M
Q2 24
$5.2M
$-24.1M
Q1 24
$3.4M
$27.0M
FCF Margin
CTKB
CTKB
MSTR
MSTR
Q4 25
-2.9%
Q3 25
-8.7%
-8.6%
Q2 25
-3.2%
-32.3%
Q1 25
-2.3%
-4.6%
Q4 24
1.9%
-14.6%
Q3 24
23.7%
-35.7%
Q2 24
11.0%
-21.6%
Q1 24
7.6%
23.5%
Capex Intensity
CTKB
CTKB
MSTR
MSTR
Q4 25
1.6%
Q3 25
1.3%
2.2%
Q2 25
3.5%
1.8%
Q1 25
2.0%
2.5%
Q4 24
1.6%
0.2%
Q3 24
2.0%
0.4%
Q2 24
2.3%
0.6%
Q1 24
1.3%
1.3%
Cash Conversion
CTKB
CTKB
MSTR
MSTR
Q4 25
Q3 25
-0.00×
Q2 25
-0.00×
Q1 25
Q4 24
0.21×
Q3 24
14.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

MSTR
MSTR

Segment breakdown not available.

Related Comparisons